Entera Bio (ENTX) Receivables (2018 - 2025)

Entera Bio (ENTX) has reported Receivables for 8 consecutive years, with $126000.0 the latest figure, recorded in Q1 2025.

• Quarterly Receivables changed N/A year-over-year to $126000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $126000.0 (changed N/A YoY) and the FY2024 annual result came in at $126000.0, changed N/A from the prior year.
• Receivables steadied at $126000.0 in Q1 2025 per ENTX's latest filing, from $126000.0 in the prior quarter.
• Over the last five years, Receivables for ENTX reached as high as $246000.0 in Q4 2022 and fell as low as $29000.0 in Q1 2023.
• A 5-year average of $135166.7 and a median of $126000.0 in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables sank 87.11% — and 2024, when it surged 96.55%.
• Year by year, Receivables stood at $183000.0 in 2021, then surged by 34.43% to $246000.0 in 2022, then tumbled by 88.21% to $29000.0 in 2023, then jumped by 334.48% to $126000.0 in 2024, then changed by 0.0% to $126000.0 in 2025.
• According to Business Quant data, Receivables over the past three periods registered $126000.0, $126000.0, and $42000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.